DCF Tool


Perrigo Company plc – Pharmaceutical Preparation Manufacturing
perrigo company plc, a top five global over-the-counter (otc) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. from its beginnings in 1887 as a packager of generic home remedies, perrigo, headquartered in ireland, has grown to become the world's largest manufacturer of otc products and supplier of infant formulas for the store brand market. the company is also a leading provider of branded otc products, generic extended topical prescription products and receives royalties from multiple sclerosis drug tysabri®. perrigo provides “quality affordable healthcare products®” across a wide variety of product categories and geographies primarily in north america, europe, and australia, as well as other key markets including israel and china. visit perrigo online at (http://www.perrigo.com).
Analysis Results
Intrinsic Value $85.80
Latest Price $31.49
Relative Value 63% undervalued
Thoughts on this result? Let us know.
Cash Flow (Billions)
Analysis Parameters
New Ticker
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of -3.8%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 5.4%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of -3.8%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (billion) Present value (billion)
2023 0.505 0.48
2024 0.486 0.438
2025 0.467 0.4
2026 0.45 0.365
2027 0.432 0.333
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 13.1 billion. This corresponds to a present value of 9.6 billion.

Intrinsic Value Per Share

The total present value of the projected cash flows is 2.02 billion. Adding in the terminal value gives a total present value of 11.6 billion.

There are presently 135.0 million outstanding shares, so the intrinsic value per share is 85.8.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 2,719,900,000
Current Cash 600,800,000
Current Liabilities 1,113,600,000
Current Debt 36,200,000
Non-Cash Working Capital (NCWC) 1,041,700,000
Change in NCWC 31,200,000
EBIT 121,400,000
Tax Provision -8,200,000
Depreciation and Amortization 338,600,000
Capital Expenditure -96,400,000
Unlevered Free Cash Flow 394,800,000
Current Assets 3,859,900,000
Current Cash 1,865,300,000
Current Liabilities 1,587,900,000
Current Debt 603,800,000
Non-Cash Working Capital (NCWC) 1,010,500,000
Change in NCWC -134,800,000
EBIT 600,400,000
Tax Provision 389,600,000
Depreciation and Amortization 312,200,000
Capital Expenditure -152,100,000
Unlevered Free Cash Flow 236,100,000
Current Assets 3,133,500,000
Current Cash 644,000,000
Current Liabilities 1,382,000,000
Current Debt 37,800,000
Non-Cash Working Capital (NCWC) 1,145,300,000
Change in NCWC 81,700,000
EBIT 465,700,000
Tax Provision 13,200,000
Depreciation and Amortization 384,800,000
Capital Expenditure -170,400,000
Unlevered Free Cash Flow 761,800,000
Current Assets 2,756,900,000
Current Cash 360,900,000
Current Liabilities 1,335,800,000
Current Debt 3,400,000
Non-Cash Working Capital (NCWC) 1,063,600,000
Change in NCWC 69,100,000
EBIT 415,600,000
Tax Provision 24,900,000
Depreciation and Amortization 396,500,000
Capital Expenditure -137,700,000
Unlevered Free Cash Flow 682,982,807
Current Assets 2,902,200,000
Current Cash 560,500,000
Current Liabilities 1,537,400,000
Current Debt 190,200,000
Non-Cash Working Capital (NCWC) 994,500,000
Change in NCWC 219,200,000
EBIT 481,900,000
Tax Provision 159,600,000
Depreciation and Amortization 423,600,000
Capital Expenditure -102,600,000
Unlevered Free Cash Flow 757,436,407
Current Assets 2,819,600,000
Current Cash 678,700,000
Current Liabilities 1,436,000,000
Current Debt 70,400,000
Non-Cash Working Capital (NCWC) 775,300,000
Change in NCWC -144,200,000
EBIT 706,700,000
Tax Provision 160,500,000
Depreciation and Amortization 444,800,000
Capital Expenditure -88,600,000
Unlevered Free Cash Flow 513,754,087
Current Assets 2,805,300,000
Current Cash 622,300,000
Current Liabilities 1,836,300,000
Current Debt 572,800,000
Non-Cash Working Capital (NCWC) 919,500,000
Change in NCWC 164,000,000
EBIT 662,300,000
Tax Provision -835,500,000
Depreciation and Amortization 457,000,000
Capital Expenditure -106,200,000
Unlevered Free Cash Flow 1,177,100,000
Current Assets 3,182,900,000
Current Cash 798,300,000
Current Liabilities 1,693,700,000
Current Debt 64,600,000
Non-Cash Working Capital (NCWC) 755,500,000
Change in NCWC -59,000,000
EBIT 752,800,000
Tax Provision 120,000,000
Depreciation and Amortization 548,800,000
Capital Expenditure -137,000,000
Unlevered Free Cash Flow 741,341,935
Current Assets 2,550,900,000
Current Cash 805,400,000
Current Liabilities 1,074,700,000
Current Debt 143,700,000
Non-Cash Working Capital (NCWC) 814,500,000
Change in NCWC 60,800,000
EBIT 620,000,000
Tax Provision 67,300,000
Depreciation and Amortization 358,900,000
Capital Expenditure -171,600,000
Unlevered Free Cash Flow 715,033,235
Current Assets 2,236,900,000
Current Cash 779,900,000
Current Liabilities 749,500,000
Current Debt 46,200,000
Non-Cash Working Capital (NCWC) 753,700,000
Change in NCWC 172,909,000
EBIT 691,000,000
Tax Provision 165,700,000
Depreciation and Amortization 160,200,000
Capital Expenditure -104,100,000
Unlevered Free Cash Flow 731,595,802
Current Assets 1,795,921,000
Current Cash 602,489,000
Current Liabilities 652,731,000
Current Debt 40,090,000
Non-Cash Working Capital (NCWC) 580,791,000
Change in NCWC 101,867,000
EBIT 577,981,000
Tax Provision 119,015,000
Depreciation and Amortization 135,323,000
Capital Expenditure -120,942,000
Unlevered Free Cash Flow 559,873,752

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.